Viatris, Opus gain as FDA to review label expansion for eyecare drug
Source: SeekingAlpha
2026-02-25 08:10:21 ET
More on Viatris, Opus Genetics
- Opus Genetics: Asymmetric Upside With LCA5 And BEST1
- Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash Generation
- Opus Genetics, Inc. (IRD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Opus Genetics higher after $25M private placement
- Viatris gains as UBS upgrades to Buy on outlook and pipeline
Read the full article on Seeking Alpha
For further details see:
Viatris, Opus gain as FDA to review label expansion for eyecare drug
Viatris Inc.
NASDAQ: VTRS
VTRS Trading
0.11% G/L:
$13.75 Last:
2,149,017 Volume:
$13.89 Open:
VTRS Latest News
February 27, 2026 03:57:23 pm
Bastion Bets on Government Spending with $8 Million New Stake in Parsons
February 26, 2026 06:55:00 am
Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend
VTRS Stock Data
$18,451,353,349
1,140,252,173
N/A
503
N/A
Pharmaceuticals
Healthcare
US
Canonsburg
